Podcasts about quantgene

In this day and age, young people are now getting cancer at a tremendous rate.A constant worry in all our families is the fear that a family member - old or young - would suddenly emerge as someone who is battling the late stages of cancer. This would usually lead to thousands of dollars availing of treatment for an illness that's already widespread within the body without assurance that the cancer cells will be depleted in the body enough to consider the individual recovered. With that in mind, Quantgene is setting a new standard in the medical field as they conduct liquid biopsy partnered with the DNA Company's genomic tech.In this episode, Tracy Wood, CEO of the DNA Company, along with Dr. Krista Kostroman, CSO of the DNA Company, is joined by Jo Bhakdi, CEO of Quantgene. The trio discuss the importance of preventive care, most especially when it comes to talks of cancer detection. As mentioned in the former paragraph, it is better to detect cancer in its early stages to ensure that it doesn't come to a point where it has overtaken the body. They discuss what liquid biopsy is and its benefits when individuals invest in such tests. The episode also tackles what steps must be taken beyond detection. This means making an effort in conducting lifestyle changes and strategic prevention to take a stand against the war on cancer while all is not lost, and there's still hope.If you wish to learn more from Jo Bhakdi and Quantgene, you may do so through the following links:Jo Bhakdi's Instragram account at https://www.instagram.com/jobhakdi/Quantgene's website at https://quantgene.com/Quantgene's Instagram Account at https://www.instagram.com/quantgene/▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram https://www.instagram.com/dnatalkspodcast/Dr. Krista Kostroman's Official Instagram Page https://www.instagram.com/drkostromanofficial/This episode may also be viewed on YouTube▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Inspiring Motivational Background by Stock-Waveshttps://www.stock-waves.com/https://protunes.net/Video Link:  https://www.youtube.com/watch?v=pbwVDTn-I0o&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG&index=5▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Peaceful Corporate by Stock-Waveshttps://protunes.net/Video Link:  https://www.youtube.com/watch?v=I34bTKW8ud0&list=PLQtpqy3zeTGB7V

In this eye-opening episode, we had the privilege of sitting down with Jo Bhakdi, a visionary in the field of healthcare, to discuss the critical importance of early detection screening and preventing chronic disease. Jo Bhakdi, the founder and CEO of Quantgene, shared his insights on a wide range of topics, shedding light on why early screening is essential, how we can encourage people to prioritize prevention, advanced diagnostic/screening tools, the nuances of false positives, affordability in healthcare, the benefits of communal living, and the "Resolution" approach to healthcare. This episode is a must-listen for anyone interested in the future of healthcare and the role of early detection in achieving health sovereignty and affordable wellness.Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios.SHOW NOTES:0:51 Welcome to the show!3:34 About Jo Bhakdi4:30 Welcome him to the podcast!5:35 Why is early screening essential?10:08 How do we get people to care about prevention?10:28 Standard of Care screenings13:19 Advanced Screenings13:41 Why don't people want to screen?16:09 Prioritizing prevention17:34 Detection & False Positives23:16 Fixing the system26:22 Diagnostics: MRI, Liquid Biopsies, Blood Chem & Genomics31:50 *Troscriptions - Blue Cannatine*34:00 MRIs vs Liquid Biopsies35:18 Prostate Screening37:35 Health Sovereignty & Responsibility40:27 *Magnesium Breakthrough*42:59 Why health doesn't have to be expensive47:02 Disrupting metabolism with fad diets48:56 How & where to get started50:41 Follow-ups & “Optimizing under the Curve”52:00 The Resolution approach52:40 Neurodegeneration & Alzheimer's Prevention54:54 Medicine 2.0 & The Four Horseman1:01:20 Benefits of Living in Community1:03:57 His final piece of advice1:05:31 Where to find him1:05:54 Thanks for tuning in!RESOURCES:JoBhakdi.comhttps://getresolution.life/Website: Quantgene20QUESTIONS.LIFECHOOSESERENITY.COMINSTAGRAMFACEBOOKLINKEDINTroscriptions Blue Cannatine - discount code: BIOHACKERBABES for 10% offMagnesium Breakthrough - discount code: biohackerbabes10 for 10% offSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios. Website:https://getserenity.life/

Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios.

Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios. Jo Bhakdi

https://www.20questions.life/ https://quantgene.com/ https://getserenity.life/ Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios. ****************************************************************** Book a Coaching Call with CJ Now! Book a Coaching Call with CJ now! p-hanger.de PENIS HANGER where all MHS podcast listeners can go to get 20 percent off with the code MHS20. Jelq2Grow the best Cream on the Market specifically made for PE and recovery! IG: @masculine_health_solutions.pe IG: @crodzfit Masculine Health Solutions YouTube Channel! How to Make Your Penis Bigger EBOOK

What are the questions your listeners should ask themselves and their doctors right now that could save their lives? Dr. Jeffrey Gladden and Joe Bhakdi discuss that in this episode of the Gladden Longevity Podcast. Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X. This investment platform provides quantitative analytics for biotechnology and technology portfolios. This episode discussed early detection – how it can save lives and how being vigilant can protect you for years to come. They also delve into how there is a care gap in American health care and what can be done to mend it. Should health care be a priority for everyone for a longer life?  Listen to this episode to learn about making 100 the new 30, and living young for a lifetime!  -- DISCOUNT:   Podcast10 (10% off your purchase at the Gladden Longevity Supplement shop (https://gladdenlongevityshop.com/)  --   Dr. Gladden talks about today's podcast interview with Jo Bhakti on the preemptive diagnosis. (00:31)  Dr. Gladden speaks about what he has learned about heart attacks. (4:25)  Human money comes with strings attached, and caution is needed. (06:36)  Dr. Gladden says cheating is a function of stakeholders' investment and interest in the outcome. (8:40)  Interest in medicine led to studying economics, strategy, innovation, and venture capital. (11:09)  Jo gives details about his journey and starting a new company. (13:43)  Jo gives insight that risk is not a bad thing but it means volatility. (14:53)  Jo takes us through what Quantgene does. (17:10)  DNA sequencing: How it works and challenges. (20:13)  Dr. Gladden notes to find something preemptively is hard work. (23:26)  "Complex liquid biopsies combine high-tech modalities." (24:06)  "Multiple biological ages critical for longevity". (28:39)  Dr. Gladden notes that there are some hallmarks of aging. (30:48)  Jo believes that cancer mutations happen before the cancer is treated. (34:30)  Serenity offers an affordable early detection package. (37:16)  Dr. Gladden explains that most people are afraid of being diagnosed. (40:14)  Time, identity, and health. (44:12)  Many people feel like a lot of diagnosis are untreatable. (46:55)  Future systems watch over and optimize health efficiently. (48:43)  Jo emphasizes that you need to develop systems for your health.  (51:15)           Visit our website, www.gladdenlongevitypodcast.com, for more information on this episode and other episodes as well. Click on the link to let us know what you'd like us to talk about on the podcast too!                           Follow us on social media!                                     Instagram: @gladdenlongevity                                     Twitter: @gladdenlongevit                                     Facebook: @GladdenLongevity                              LinkedIn: @GladdenLongevity    For more information on our practice or how to become a client, visit:   www.gladdenlongevity.com  Call us: 972-310-8916  Or email us: info@gladdenlongevity.com    To learn more about Jo Bhakdi, Quantgene and Serenity, check out the following:   Website: http://www.20questions.live/   Website #2: https://www.chooseserenity.com/   Instagram: https://www.instagram.com/choose_serenity/   Personal Website: https://www.jobhakdi.com/

Jo Bhakdi is the Founder and CEO of Quantgene with the mission to extend the healthy human life span by a decade within a decade. Together with Quantgene's team of scientists and engineers, he is dedicated to introducing cloud, AI and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life.   Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios.   Learn more and answer the 20 questions that could save your life at https://www.20questions.life/ & https://getserenity.life/store   Learn more about working with Anthony 1-on-1 to biohack your six pack, sharpen your mind, and optimize your most important longevity biomarkers at www.BiohackerCoaching.com   - Grab your free copy of The Biohacker's Guide to Upgraded Energy and Focus (just help with s/h) https://biohackersguide.com/free-guide   - Subscribe to our free email newsletter www.biohackersguide.com/energycrash    - Subscribe to The Biohacking Secrets Show podcast https://podcasts.apple.com/us/podcast/the-biohacking-secrets-show/id1139825099   Join Our Uncensored Telegram Channel for VIP Biohacking Content You Can't Get On Social

REJUVENAGING with Dr. Ron Kaiser is a podcast hosted by Ron Kaiser, a positive Health Psychologist, coach, keynote and TEDx speaker, and author of the award-winning book, "REJUVENAGING: The Art and Science of Growing Older Within Enthusiasm." The podcast aims to help listeners lead enthusiastic lives and explores various ways to become better and healthier versions of themselves. In this particular episode, Dr. Ron Kaiser welcomes Jo Bhakdi, the founder and CEO of Quantgene, a company dedicated to extending the healthy human lifespan using artificial intelligence and other new technologies.The episode focuses on the use of artificial intelligence and precision diagnostics in working toward the goal of preventing disease and improving overall health. Jo and his team at Quantgene have developed a platform called "20Questions," which asks users a series of personal health questions to identify potential health risks and provide accessible next steps for preventive care. The platform aims to bridge the gap between early detection and late-stage diseases, emphasizing the importance of early intervention to increase survival rates and prevent chronic conditions.During the conversation, Dr. Ron and Jo discuss the challenges in implementing advanced medical technologies and the barriers that prevent their widespread adoption. They touch upon the role of regulations, physician training and incentives, and the need for a shift towards precision medicine and comprehensive medical intelligence.Jo explains the vision for the future of healthcare, where individuals have access to a medical intelligence system like his company's Serenity system. This system would analyze personal health data, including genetic information, family history, and medical history, to provide individuals with personalized recommendations for preventive screenings and interventions. The goal is to create a holistic and intelligent approach to healthcare, where individuals receive coordinated care and guidance to stay ahead of diseases and optimize their well-being.The episode concludes with a discussion on the importance of having a local physician to coordinate care, while Quantgene and Serenity act as an additional layer of medical intelligence to ensure comprehensive and informed decision-making.Overall, the episode highlights the potential of artificial intelligence and precision diagnostics in revolutionizing healthcare and empowering individuals to take proactive steps towards a healthier and longer life.Connect with Jo:https://www.instagram.com/jobhakdi/?igshid=YmMyMTA2M2Y%3Dhttps://www.linkedin.com/in/jo-bhakdi-5048811/https://twitter.com/JOBhakdihttps://www.jobhakdi.comUseful REJUVENAGING® ResourcesWebsite: https://www.thementalhealthgym.com/ Hosted on Acast. See acast.com/privacy for more information.

Cancer is the number two cause of death worldwide, and despite 100s of billions invested, there is still no cure, only treatments. The treatments we do have such as chemotherapy, radiation, and surgery, while extremely aggressive, work very well if detection is early. Since there are dozens of types of cancer, screening and detection has proven challenging–but that might be changing. My guest on this week's podcast is on the forefront of genomic medicine and hopes to make early screen accessible to everyone. Listen and learn: How new technology allows for blood plasma scanning of cell-free DNA (cfDNA) to find tiny particles from cancers The role of full body MRI in cancer screening Why it currently costs thousands per year but could end up costing a fraction of this in the future Links GetSerenity.live ABOUT OUR GUEST Jo Bhakdi is the Founder and CEO of Quantgene, a precision genomics and oncology company founded in 2015. Quantgene's goal is to build the future of medicine by utilizing advanced scientific and technological innovations. Like the Show? Leave us a review Check out our YouTube channel Visit www.yogabody.com

In our final episode of season 11, Aalia is joined by Johannes Bhakdi, the Founder and CEO of Quantgene. Jo brings his expertise in the biotech industry as they discuss the use of AI and genomics in preventative healthcare, to aid in the early detection and prevention of diseases. They also talk about the role emotional intelligence plays in the industry. Jo highlights the potential of genomics and AI in developing personalized treatment plans and bridging gaps in healthcare access. He also shares Quatgene's goals to make preventative care more accessible to all, and extend the healthy human lifespan by a decade within the next decade. Like, comment, and subscribe! Stay connected with your host on IG: @aalia_unsugarcoated Stay connected to our guest: @quantgene UNSUGARCOATED™ Media is a 501c3 media enterprise, using podcasts, print publications, short documentaries, and more to tell stories of empowerment in the face of adversity and trauma. For more information on our goals, content, and sponsorship opportunities, please visit our website.

The difference between early and late detection can often mean the difference between life and death. In fact, detecting breast and colon cancer at stage 4 increases survival rates by 71-77%. Early intervention can reverse 80% of type 2 diabetes diagnoses and prevent 34% of deaths caused by heart disease.Jo Bhakdi is the Founder and CEO of founder and CEO of Serenity, the most advanced genomic and AI-driven preventative care system in the world, created to serve the overarching goal of extending the human lifespan by a decade within a decade. Their new preventative healthcare platform 20QUESTIONS.live will launch on March 1, 2023., AI, and precision diagnostics into the standard of care to enhance the quality and accessibility of care for everyone and protect human life. Born to scientist parents, Jo grew up with a backdrop of medical research before earning a Master's in Economics from Tubingen University, one of Germany's leading academic institutions. Prior to Quantgene, Jo held executive positions at BDDO and Omnicom with a focus on business model innovation and technology, then founded i2X, an investment platform that provides quantitative analytics for biotechnology and technology portfolios.What you will discover:What led to developing the 20 Questions system (5:32)How 20 Questions can help people who have become distrustful of the medical industry (17:00)The importance of becoming your own CEO for your health (23:08)AI and the 20 Questions and how they are adaptive to each individual (26:55)Genetics vs environmental (42:48)Connect with Jo:Email WebsiteInstagram Linkedin Let's Connect!WebsiteInstagramFacebookRumbleYoutube Hosted on Acast. See acast.com/privacy for more information.

On this episode of StartUp Health NOW, we're talking with Jo Bhakdi, CEO & Founder of Quantgene, a company that joined StartUp Health in 2019. Bhakdi and his team have made a name for themselves by offering a kind of deep genomic profiling that allows them to identify cancers early, detect hereditary diseases, and find adverse drug interactions. The name of the game here is genomic medicine and we're not talking about 23andMe or Ancestry.com. As you'll hear in the interview, Bhakdi has a revolutionary vision for where the field of genomic medicine is heading in the next five years. And he's got a strategy for getting there. Spoiler alert: Bhakdi believes that if we can get the cost of genomic testing down – which he's actively working on – and can scale access to genomic medicine to millions of people, that could knock cancer out of the top 10 list of leading causes of death entirely. Since cancer is currently at number two, it's a pretty radical idea, but Bhakdi has a strong track record and a compelling market strategy through Quantgene's new offering called Serenity. We'll let him explain the vision in this episode. Founders: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion Want more content like this? You can subscribe to the podcast as well as other health innovation updates at startuphealth.com/content. Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Looking to break down health barriers? If you're an entrepreneur or investor, contact us to learn how you can join our Health Equity Moonshot. Passionate about Type 1 diabetes? If you're an entrepreneur or investor, contact us to learn how you can join our T1D Moonshot.

If only we could detect all life threatening diseases before symptoms occur and early enough to reverse the course of those conditions.  We are on the cusp of being able to achieve that.  Significant, recent developments, in the field of genomic testing, mean that scientists are able to pinpoint the warning signs for some major degenerative illnesses, in time to make life-saving interventions. In this episode of the LLAMA podcast, we meet Jo Bhakdi, the founder of Quantgene, a Santa Monica based team of researchers - oncologists, clinicians, technologists, data scientists and business innovators  - who're working to change the paradigm of healthcare.  In conversation with Peter Bowes, Jo discusses his startup company's mission of defeating cancer and extending human lifespan by ten years, within the next decade. He also reflects on the exploding interest and progress in human longevity research, which has seen the field grow, exponentially, in recent years. Recorded: May 30, 2021 | Read a transcript and show notes at the LLAMA podcast websiteIn this interview we cover:The mission of Quantgene "to combine deep genomics, cloud and artificial intelligence into a new technology stack" to help detect dangerous diseases like cancer.Why the ability to get genomic data points from DNA is an "enormous game changer" in healthcare.The merging of mathematics and complex numeric problems with biology and medicine. Quantgene's mission of extending the human lifespan by ten years within the next decade. The business model, cautious investors and taking the technology to the next levelTaking the tests - what does it involve?Understanding how medicine and diagnostic work, plus the value of lifestyle information. What it means to overlay the conventional care system with one based on genomic science, such as Quantgene Serenity.What about people who would simply rather not know about the diseases they are predisposed or likely to develop? Tying to convince health systems and governments to embrace new ways to diagnose potential ill health. Adopting a radical philosophy about personal longevity. Leveraging the "natural stuff" to live long and well. Given the current science, what is a realistic, maximum lifespan? The Live Long and Master Aging podcast, a HealthSpan Media LLC production, shares ideas but does not offer medical advice.  If you have health concerns of any kind, or you are considering adopting a new diet or exercise regime, you should consult your doctor.: 

Cloud computing is helping revolutionize the personalized healthcare space with 21st century Computer-Aided Biology tools. Next generation sequencing technologies capable of generating more data than ever before, the storage, processing and analysis of that data is more than a single machine can handle. Enter the cloud. In this episode we talk with Jo Bhakdi, CEO of Quantgene, a company bringing the power of next generation deep sequencing to liquid biopsies to search for early signs of cancer. He tells us how the cloud plays a critical role in managing all that data and how their technology aims to increase the human life span by a decade within a decade. Quantgene are working with Serenity, a system which utilizes Quantgene's liquid biopsy and AI, and has turned it into a customer-facing product. For US customers who are interested in liquid biopsy for early cancer signal detection and whole exome sequencing, and who want to incorporate the Serenity system into a preventative health plan, visit www.chooseserenity.com and use the discount code CAB15 for 15% off at checkout.

Today, we are privileged to feature the outstanding Jo Bhakdi, Founder and CEO of Quantgene. Jo discusses how his company is building the most advanced genomics technology that can detect cancer and other diseases earlier, while they are easier to treat. He talks about the genesis of the Quantgene, the benefits of merging genomic sequencing with AI, Serenity System and it's amazing ability to detect diseases, the challenges they faced, and many more. Jo and his team are building the future of medicine, which is so exciting. Learn more about Quantgene and how it can impact healthcare in this podcast episode. Click this link to the show notes, transcript, and resources: outcomesrocket.health

Our guest: Jo Bhakdi, Founder & CEO at Quantgene. "Quantgene is building the future of medicine by engineering the most advanced scientific and technological innovation that unlock the Deep Human Genome." For more information on the Serenity product, visit www.chooseserenity.com and use the discount code "Sliceofhealthcare10" for 10% off all Serenity products. On this episode, we discussed: - His background - How he got to where he is today - What is Quantgene? - What's next? - ...and much more! Our sponsors for this episode are BlocHealth and Curation Health. BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. Through their platform, healthcare professionals and organizations can enter, upload and share core credentialing documents and information. Professionals and organizations then have the opportunity to use that information to order multiple services and solutions like credentialing, state license registration, certifications, payer enrollment, renewals, and more! On average, the BlocHealth platform saves users 40-60% on credentialing and licensing-related costs. Organizations can use BlocHealth as an extension of their team, or as their whole licensing and credentialing team. For more information, please go to www.blochealth.com and be sure to follow BlocHealth on social media - @blochealth "Curation Health’s advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to www.curationhealthcare.com and be sure to follow Curation Health on social media - @curationhealth To learn more about Quantgene please use the links below: - Website - LinkedIn - Twitter - Facebook Also, be sure to follow Slice of Healthcare on our social channels: - Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

Quantgene has combined precision genomics, machine learning, and a new perspective to detect cancers at early stages. By doing this they have brought one of the biggest needle movers to the market for beating cancer, catching it at an early enough stages for treatments to be effective. Jo discusses some of the science, approach, and system his company is taking to advance a new model for early cancer detection. Join us for the full episode!

Jo Bhakdi wants to build a future where people are protected against most diseases through early detection. His company Quantgene, which marries artificial intelligence with the ability to detect cell-free DNA in the blood with great sensitivity, believes it can help extend the lives of its customers by ten years within ten years. Quantgene is offering both its Serenity subscription service to consumers, as well as other offerings to therapeutic developers to support R&D using its technology. We spoke to Bhakdi, founder and CEO of Quantgene, about his unusual path to becoming a precision medicine CEO, how he expects technology to transform healthcare, and why he believes the company will be able to extend the lives of its customers through early detection of disease.

Cancerous tumors have their own microbiome, a unique method of energy production, strategies for evading host immune systems, specialized extracellular vesicles, and one real goal: to expand and replicate at the expense of the environment. Press play to discover: What major transformation in tumor detection and diagnosis is on the horizon and holds promise for very early and accurate cancer detection (and why the current methods of screening/detection/diagnosis are so bad) What specific ability allows cancer to kill its host Why the theory behind chemotherapy is wrong, and how it actually puts accelerated selection pressure on tumors   Returning guest, Jo Bhakdi, is the founder of Quantgene, the world's leader in liquid biopsy technologies when it comes to precision. It's a technology that uses next-generation genome sequencing in combination with AI and cloud systems to detect cancer in the early stages in the blood. The team at Quantgene has pioneered the ability to have single-molecule precision across a very high number of locations on DNA. This core sequencing technology is being embedded in advanced AI cloud systems that also have whole exome sequencing data. Together with genetics, medical records, and family history data, these technologies render a 360-degree precision profile for each patient. In essence, it's a giant, sensitive detection tool for cancer, and it holds promise for fulfilling the same role for other diseases. Bhakdi discusses all aspects of cancer, including how it spreads, how it's acted upon epigenetically, and the potential of certain therapies. In particular, he says, “One of the greatest breakthroughs in my opinion, that is not fully exploited yet, is immunotherapy, because every time you have something very complex…you need another system that's equally complex and capable to indirectly handle it.” He talks about the indirect screening trade-offs of liquid biopsies, the general problem of over-diagnosing, the relationship between the heterogeneity of tumors and mutation profiles, and more.     Learn more at https://www.quantgene.com/. Available on Apple Podcasts: apple.co/2Os0myK

Returning guest and founder of Quantgene, Jo Bhakdi, discusses his work at Quantgene in the COVID-19 testing arena. Press play to learn: What the difference is between specificity and sensitivity, and why a consideration of both is critical for COVID-19 testing What the difference is between antigen, antibody, and PCR-based COVID-19 test procedures, and why Bhakdi believes it is so important to develop real-time rapid PCR-based testing for COVID-19 How the specific virus causing COVID-19 is able to be isolated and identified through PCR-based testing Quantgene's genomic and liquid biopsy technologies have played a significant role in advancing the speed and accuracy of cancer identification. Now, they're focusing their efforts on COVID-19 testing methods. “We are all about real-time medical intelligence,” says Bhakdi, as he explains that medicine is mostly a data problem, with the COVID-19 situation being no exception. According to Bhakdi, the COVID-19 testing crisis is not a molecular diagnostic problem, but a time problem: it's simply taking far too long for people to get their results. Bhakdi explains what PCR testing is and how it works. This includes an explanation of how the amount of genomic material doubles with each amplification cycle in the PCR procedure, in what way the test involves DNA sequencing, and the role of the protein polymerase in synthesizing strands of DNA. He also explains what Quantgene's COVID-19 test provides that others don't, and the enormous demand for a reliable test that delivers fast results.  Visit https://www.quantgene.com/ to learn more. Available on Apple Podcasts: apple.co/2Os0myK

Want to learn more about personal development and living your best life? Check us out https://www.pursuinggreatnesspodcast.comEnjoy the show? Support us by sharing this episode with your friends and subscribing to the channel for all our upcoming interviews and episodes on becoming successful, realizing your potential, and living your best life.************************************************************************EPISODE SYNOPSISIn this episode I interview Joe Bhakdi. Jo is the CEO and Founder of Quantgene and has tremendous insight into genomic diagnostics, early disease detection and precision medicine. Jo brings some insightful wisdom on modern day health and living your best life, so strap in, grab your pen and paper and enjoy the show.CATEGORY:   Health, Nutrition, and Fitness************************************************************************GET INVOLVED, CONNECTED & EDUCATEDLEARN -- Want to learn more about personal development and living your best life? Check us out https://www.pursuinggreatnesspodcast.comLEARN -- Want to achieve financial and time freedom by learning real estate investing? Check out our real estate investing podcast at https://www.therealestateinvestingclub.comWATCH -- Want to watch our YouTube channel? Click here: https://www.youtube.com/channel/UC5VdXsdmf6iuH4Q37lN_1hg?sub_confirmation=1READ -- Want book recommendations? Check out our list of the best books on personal development: https://www.gabepetersen.comLISTEN -- Want to listen to our wisdom Podcast? Go here: https://pursuinggreatness.buzzsprout.com************************************************************************GUEST RECOMMENDED BOOKSThe Making of the Atomic Bomb - https://amzn.to/3gzEGNa************************************************************************ABOUT THE GUESTMy name  is Jo Bhakdi, and I'm the founder and CEO of Quantgene. My team's work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.Website: https://www.quantgene.com/about-us**********************************************************************ABOUT PURSUING GREATNESS THE YOUTUBE SHOW AND PODCASTPursuing Greatness is an interview based podcast and YouTube show where high performers and people from all walks of life share their best advice, greatest stories, and favorite tips in the art of success, flourishing and living your best life. Join us as we delve into every aspect of personal development - from mastering your business, money, work and wealth, to perfecting your health and energy, to growing in love and relationships.Support the show (https://paypal.me/GabrielWPetersen?locale.x=en_US)

Returning guest Jo Bhadi discusses using new platforms and technologies to predict cancer probability as well as what he's learned about how cancer evolves. He also discusses how Quantgene seeks to serve its customers. He addresses How Quantgene uses the human genome sequence, artificial intelligence, liquid biopsies, and other technology platforms to identify cancer patterns; How they've put together a monthly subscription turnkey service for early cancer detection; and How cancer itself develops and how they approach detection with this layering of different types of information to achieve a specificity of detection above 90%. Jo Bhakdi started Quantgene in 2015 at a UC Berkeley Lab with a goal of early disease detection. The company uses quantitative science for a new level of precision. They started in cancer detection spaces using cell-free DNA sequencing with what is known about the human genome sequence. They saw a tremendous opportunity opening up based on new technology platforms, sequencing, and AI recognition algorithms. In a nutshell, they pursued how to look at cell-free DNA shed by cancer in the bloodstream and recognition patterns to identify the 15 most deadly cancers. They sell their services directly to patients but include physicians and genetic counselors in the process.  He explains their business model in further detail but also covers the complications of detecting and understanding cancer progression, from the heterogeneity of tumors to advantages of cell-free DNA sequencing compared to tumor biopsies. He explains the systemic insight into cancer a liquid biopsy offers.  He describes other limitations of tumor biopsies and how the question of heterogeneity of a tumor is surprisingly complex. In fact, he adds that the whole concept of quantifying tumor heterogeneity is a very new concept. He describes many characteristics of cancer and its evolution in more detail and then addresses how Quantgene layers many degrees of information, including medical and genetic history, to produce a highly precise probabilistic model.  For more about the company, see quantgene.com. To find out about the direct-to-consumer service, see chooseserenity.com. Available on Apple Podcasts: apple.co/2Os0myK

By Michael Tetreault, Editor-in-Chief Today we sit down with the two leaders in the cancer testing, genetics and precision medicine space. Cancer is routinely a concern for Doctors and Patients and preventing, testing and catching it early is so important. Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine. Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform. Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany's leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions. Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all. Meet Dr. Monika E. Hagen, MD, MBA Monika E. Hagen, MD, MBA is the Chief Medical Officer of Quantgene and a board certified General Surgeon, specializing in bariatric surgery. Trained in Germany, Switzerland, and the United States, she has over a decade of experience as a medical doctor, academic surgeon, teacher, medical device expert, and clinical trial specialist. She also received her MBA from the University of Wales in Cardiff, UK. Dr. Hagen is an international thought leader and lecturer in bariatric and minimally invasive surgery, as well as surgical robotic technology and its clinical applications. She is a frequent speaker at medical conferences and has published extensively on topics ranging from robotic surgery, to clinical trial design to the future of medicine. Prior to joining Quantgene and utilizing her clinical, strategic planning, and business development expertise, she has served as a regular consultant to financial, technology, medical, and biotech companies. Dr. Hagen divides her time between professional roles in Geneva, Switzerland, Silicon Valley, and Santa Monica, California. Resources Discussed In Today's Interview https://chooseserenity.com/ https://www.quantgene.com/about-us For more information, please visit: https://www.quantgene.com/ . Contact Information: Rachel Strohmeyer and Jo Bhakdi, CEO - jb@quantgene.com Quantgene 951-775-0607 rachel@quantgene.com

Quantgene can detect early-stage cancer in a single draw of bloodWhat we are doing is a potential game-changer in medicine. … it makes the detection [of dead cells form tumors] single-molecule precise. Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene  The FounderIn this interview, we talk to Johannes “Jo” Bhakdi (https://www.linkedin.com/in/jo-bhakdi-5048811/), originally born and raised in the Rhine-Main Area in Germany, but now founder of the AI and Big Data Startup Quantgene (https://www.quantgene.com/, https://www.crunchbase.com/organization/quantgene) in Santa Monica, CA. Quantgene describes itself as a deep genomics startup. They also have an office in Berlin and they hire for both locations. By training Jo is an economist, who graduated from the University of Tübingen (https://en.wikipedia.org/wiki/University_of_T%C3%BCbingen), a research-heavy university known for its 11 Nobel Laureates in Medicine, Chemistry, and Physics. Jo started out in advertising and marketing (marketing strategy). He went from there in corporate development, especially mergers and acquisitions. This brought to the USA, first to New York with a stop in venture capital. He was working with his first startup in quantitative seed-stage investments. What we developed is blood test, that guides physicians in detection of early stage cancer. Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene   Affiliate LinksIs your startup in need of a bank account in Germany? Try our partner affiliate Penta http://bit.ly/3bdHX3d Looking to open a bank account to shift between crypto and fiat? Try our partner Bitwala with this affiliate link here http://bit.ly/2w01Zye    The Startup  To give you an idea of what we are doing: It is a few megabytes – a simple sequencing of your genome. What we are doing generates files of 200+ Gigabytes Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene   Quantgene is a deep tech startup, working with ai, machine learning, and big data to fight cancer. They describe themselves as a deep genome startup. Quantgene is working on unlocking specific hints about cancer in the human genome since cancer is “encoding” itself into the human genome. Quantgene developed a very specific new capability to unlock the human genome of a very deep level. Startups like 23andme generate averages in genome sequencing, a kind of simplification. Quantgene's approach, on the other hand, is much more specific, but also very complex. They are looking for dead cancer cells – so-called cell-free DNA – in your blood sample. This only works if they are not working with averages but analyze a single copy of DNA in a sample. They had to develop a vast software infrastructure and their own chemistry to make their idea work. Quantgene also has an office in Berlin, from which Jo joined the Startuprad.io interview. They call it the “Mustererkennungs Einheit” which means the pattern recognition unit. Quantgene launches in 2020 (as planned before Corona) first in the USA and within some time they want to launch in Germany, Austria, and Switzerland.   When you have very early cancer, no one can see, and no one can find – with the current methods. The cancer cells die, and they shed the dead cells into your blood. So they are in your blood as cell free DNA. Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene     The Video Interview is set to go live on May 7th 19.00 CET(1 pm Eastern, 18.00 London )

Quantgene combines deep genomics with AI to detect cancer very early. When you listen, you'll hear Mr. Bhakdi explain: What information they are able to glean from a blood test regarding cancer presence. The difference and benefit of a "liquid biopsy" or blood test compared with a conventional tumor biopsy. How this test is able to recognize mutational expressions despite the heterogeneity of most tumors. Quantgene founder and CEO Jo Bhakdi discusses the company's focus on early cancer detection through blood testing to find its earliest markers. With a human genome sequence software-driven technology that also engages chemistry, machine learning, and laboratory processes, Quantgene is able to sequence and investigate cancer DNA one by one. This increases the accuracy and speed by an exponential degree compared to other detections that were based on protein marker identification. The test can pick up somatic DNA mutations in the blood caused by tumors with a whole new level of precision by detecting individual molecules in cancer DNA. This human genome sequence work is superior to next generation sequencing because it's much more accurate.  Quantgene's process can investigate every single DNA copy and eliminate any errors. They aggregated the world's largest data set of tumor DNA and created a matching learning project to answer very specific questions like, what are the smallest number of locations one has to look at to still find any variant of a tumor? They can get a systemic reflection of the tumor and can tell exactly what the tumor is in mutational terms. The data they've generated and continue to generate is completely new in oncology. Future plans include the launch of an early detection product in 2020 called Serenity. A simple blood test done once a year should guide physicians on detecting cancer early. The resulting data set will create much larger data sets ultimately, with a huge data flow to gain full scientific insight. For more information on the company, see https://www.quantgene.com/ For more on the 2020 test release of Serenity, see https://www.quantgene.com/early-cancer-detection